<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Immunology</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1664-3224</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7994782</article-id>
    <article-id pub-id-type="doi">10.3389/fimmu.2021.639491</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Immunology</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>VaximmutorDB: A Web-Based Vaccine Immune Factor Database and Its Application for Understanding Vaccine-Induced Immune Mechanisms</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Berke</surname>
          <given-names>Kimberly</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/1197474/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sun</surname>
          <given-names>Peter</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/1166247/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ong</surname>
          <given-names>Edison</given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
          <sup>3</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/470589/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sanati</surname>
          <given-names>Nasim</given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
          <sup>4</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/397554/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Huffman</surname>
          <given-names>Anthony</given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
          <sup>3</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/1014856/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Brunson</surname>
          <given-names>Timothy</given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Loney</surname>
          <given-names>Fred</given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ostrow</surname>
          <given-names>Joseph</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Racz</surname>
          <given-names>Rebecca</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhao</surname>
          <given-names>Bin</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Xiang</surname>
          <given-names>Zuoshuang</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Masci</surname>
          <given-names>Anna Maria</given-names>
        </name>
        <xref ref-type="aff" rid="aff5">
          <sup>5</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/49071/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zheng</surname>
          <given-names>Jie</given-names>
        </name>
        <xref ref-type="aff" rid="aff6">
          <sup>6</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wu</surname>
          <given-names>Guanming</given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
          <sup>4</sup>
        </xref>
        <xref ref-type="corresp" rid="c001">
          <sup>*</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/553119/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>He</surname>
          <given-names>Yongqun</given-names>
        </name>
        <xref ref-type="aff" rid="aff7">
          <sup>7</sup>
        </xref>
        <xref ref-type="aff" rid="aff8">
          <sup>8</sup>
        </xref>
        <xref ref-type="aff" rid="aff9">
          <sup>9</sup>
        </xref>
        <xref ref-type="corresp" rid="c002">
          <sup>*</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/16321/overview"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>College of Literature, Science, and the Arts, University of Michigan</institution>, <addr-line>Ann Arbor, MI</addr-line>, <country>United States</country></aff>
    <aff id="aff2"><sup>2</sup><institution>Central Michigan College of Medicine</institution>, <addr-line>Mt. Pleasant, MI</addr-line>, <country>United States</country></aff>
    <aff id="aff3"><sup>3</sup><institution>Department of Computational Medicine and Biology, University of Michigan</institution>, <addr-line>Ann Arbor, MI</addr-line>, <country>United States</country></aff>
    <aff id="aff4"><sup>4</sup><institution>Department of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University</institution>, <addr-line>Portland, OR</addr-line>, <country>United States</country></aff>
    <aff id="aff5"><sup>5</sup><institution>Department of Biostatistics and Bioinformatics, Duke University School of Medicine</institution>, <addr-line>Durham, NC</addr-line>, <country>United States</country></aff>
    <aff id="aff6"><sup>6</sup><institution>Department of Genetics, University of Pennsylvania Perelman School of Medicine</institution>, <addr-line>Philadelphia, PA</addr-line>, <country>United States</country></aff>
    <aff id="aff7"><sup>7</sup><institution>Unit for Laboratory Animal Medicine, University of Michigan Medical School</institution>, <addr-line>Ann Arbor, MI</addr-line>, <country>United States</country></aff>
    <aff id="aff8"><sup>8</sup><institution>Department of Microbiology and Immunology, University of Michigan Medical School</institution>, <addr-line>Ann Arbor, MI</addr-line>, <country>United States</country></aff>
    <aff id="aff9"><sup>9</sup><institution>Center for Computational Medicine and Biology, University of Michigan</institution>, <addr-line>Ann Arbor, MI</addr-line>, <country>United States</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p>Edited by: Julio Aliberti, National Institute of Allergy and Infectious Diseases (NIH), United States</p>
      </fn>
      <fn fn-type="edited-by">
        <p>Reviewed by: Han Sang Yoo, Seoul National University, South Korea; Renukaradhya J. Gourapura, The Ohio State University, United States</p>
      </fn>
      <corresp id="c001">*Correspondence: Guanming Wu <email>wug@ohsu.edu</email></corresp>
      <corresp id="c002">Yongqun He <email>yongqunh@med.umich.edu</email></corresp>
      <fn fn-type="other" id="fn001">
        <p>This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology</p>
      </fn>
      <fn fn-type="other" id="fn002">
        <p>†These authors share first authorship</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>12</day>
      <month>3</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2021</year>
    </pub-date>
    <volume>12</volume>
    <elocation-id>639491</elocation-id>
    <history>
      <date date-type="received">
        <day>09</day>
        <month>12</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>18</day>
        <month>2</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2021 Berke, Sun, Ong, Sanati, Huffman, Brunson, Loney, Ostrow, Racz, Zhao, Xiang, Masci, Zheng, Wu and He.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <copyright-holder>Berke, Sun, Ong, Sanati, Huffman, Brunson, Loney, Ostrow, Racz, Zhao, Xiang, Masci, Zheng, Wu and He</copyright-holder>
      <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>Vaccines stimulate various immune factors critical to protective immune responses. However, a comprehensive picture of vaccine-induced immune factors and pathways have not been systematically collected and analyzed. To address this issue, we developed VaximmutorDB, a web-based database system of vaccine immune factors (abbreviated as “vaximmutors”) manually curated from peer-reviewed articles. VaximmutorDB currently stores 1,740 vaccine immune factors from 13 host species (e.g., human, mouse, and pig). These vaximmutors were induced by 154 vaccines for 46 pathogens. Top 10 vaximmutors include three antibodies (IgG, IgG2a and IgG1), Th1 immune factors (IFN-γ and IL-2), Th2 immune factors (IL-4 and IL-6), TNF-α, CASP-1, and TLR8. Many enriched host processes (e.g., stimulatory C-type lectin receptor signaling pathway, SRP-dependent cotranslational protein targeting to membrane) and cellular components (e.g., extracellular exosome, nucleoplasm) by all the vaximmutors were identified. Using influenza as a model, live attenuated and killed inactivated influenza vaccines stimulate many shared pathways such as signaling of many interleukins (including IL-1, IL-4, IL-6, IL-13, IL-20, and IL-27), interferon signaling, MARK1 activation, and neutrophil degranulation. However, they also present their unique response patterns. While live attenuated influenza vaccine FluMist induced significant signal transduction responses, killed inactivated influenza vaccine Fluarix induced significant metabolism of protein responses. Two different Yellow Fever vaccine (YF-Vax) studies resulted in overlapping gene lists; however, they shared more portions of pathways than gene lists. Interestingly, live attenuated YF-Vax simulates significant metabolism of protein responses, which was similar to the pattern induced by killed inactivated Fluarix. A user-friendly web interface was generated to access, browse and search the VaximmutorDB database information. As the first web-based database of vaccine immune factors, VaximmutorDB provides systematical collection, standardization, storage, and analysis of experimentally verified vaccine immune factors, supporting better understanding of protective vaccine immunity.</p>
    </abstract>
    <kwd-group>
      <kwd>vaccine</kwd>
      <kwd>vaccine immune factor</kwd>
      <kwd>immunology</kwd>
      <kwd>database</kwd>
      <kwd>bioinformatics</kwd>
      <kwd>Reactome pathways</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source id="cn001">Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases<named-content content-type="fundref-id">10.13039/100015691</named-content></funding-source>
        <award-id rid="cn001">1R01AI081062</award-id>
        <award-id rid="cn001">1UH2AI132931</award-id>
      </award-group>
      <award-group>
        <funding-source id="cn002">National Human Genome Research Institute<named-content content-type="fundref-id">10.13039/100000051</named-content></funding-source>
        <award-id rid="cn002">U41HG003751</award-id>
      </award-group>
    </funding-group>
    <counts>
      <fig-count count="6"/>
      <table-count count="1"/>
      <equation-count count="0"/>
      <ref-count count="58"/>
      <page-count count="12"/>
      <word-count count="8263"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="s1">
    <title>Introduction</title>
    <p>As one of the most influential inventions in modern medicine, vaccines stimulate various immune responses in the host's body to protect it from the antigen. The common vaccine-induced immune pathways include innate responses, antigen processing and presentation, adaptive T and B cell responses, and their specific regulations (<xref rid="B1" ref-type="bibr">1</xref>). The innate immune system senses microbes through pattern-recognition receptors (PRRs) in various cells such as dendritic cells and macrophages (<xref rid="B2" ref-type="bibr">2</xref>). Important PRRs include Toll-like receptors (TLRs) (<xref rid="B3" ref-type="bibr">3</xref>), C-type lectin-like receptors (<xref rid="B4" ref-type="bibr">4</xref>), and cytosolic Nod-like and RIG-I-like receptors (<xref rid="B5" ref-type="bibr">5</xref>), which can sense various microbial stimuli. After antigen presentation, two types of adaptive immune responses can be induced: humoral response and cell-mediated immunity. The humoral response is primarily mediated by antibodies that are generated by B-cells and target specific areas of antigens. In contrast, cell-mediated immunity primarily involves the activation and production of T helper cells, cytotoxic T lymphocytes, macrophages, natural killer cells, and cytokines in response to antigens (<xref rid="B6" ref-type="bibr">6</xref>). It has also been hypothesized that vaccine-induced immune responses may have their specific immune patterns different from those of natural virulent pathogen infections (<xref rid="B7" ref-type="bibr">7</xref>).</p>
    <p>Various immune factors have been identified to be critical to vaccine-induced protective immune responses against pathogens. The importance of vaccine immune factors is clear when certain immunodeficiencies exist and protective immunity against various pathogens cannot be attained through vaccination. For example, Bruton's agammaglobulinemia is a disease which leads a lack of B cell maturation causing hypogammaglobinemia of all classes of immunoglobulin. Since the vaccine cannot induce these immune factors (immunoglobulin), a protective response cannot be formed (<xref rid="B8" ref-type="bibr">8</xref>). This same issue can be seen in other immunodeficiencies such as severe combined immunodeficiency and common variable immunodeficiency. These diseases reveal the importance of a host's response to the vaccine and how individual biology can influence vaccine efficacy.</p>
    <p>In this study, we hypothesize that different experimental and biological conditions would change vaccine-induced immune responses, which are mediated by different immune factors. The immune factor is defined as an immune-related host gene or gene-derived product such as protein in response to a specific stimulus such as vaccine. After the administration of a vaccine, an immune factor is activated to regulate and modulate the appropriate immune response in the host. Given different experimental conditions, vaccine-induced immune factors (abbreviated as “vaximmutor” in this paper) may have different profiles. The conditions may include vaccine formulation, pathogen, and vaccination route, etc. The study of vaximmutors is essential to understand immune responses of the vaccines. Understanding the similarities and differences between vaccines/vaximmutors under various experimental conditions can help decipher the biological mechanisms behind vaccine immunity and support advanced rational vaccine development. It has been shown that intrinsic factors specific to the host, such as age, genetics, sex, and comorbidities, and vaccine related factors, like adjuvants, vaccine schedule, and the specific type, strongly influence the response to a vaccine (<xref rid="B9" ref-type="bibr">9</xref>). We aim to look at the influence of experimental conditions and vaccine related factors through an in-depth look at the immune response elicited from vaccines.</p>
    <p>This article reports VaximmutorDB (<ext-link ext-link-type="uri" xlink:href="http://www.violinet.org/vaximmutordb">http://www.violinet.org/vaximmutordb</ext-link>), a web-based database that focuses on the collection, storage, annotation, and analysis of vaccine-induced immune factors. VaximmutorDB is a database under the umbrella of the VIOLIN (<ext-link ext-link-type="uri" xlink:href="http://www.violinet.org">http://www.violinet.org</ext-link>), a web-based comprehensive vaccine database and analysis system (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). VaximmutorDB also links various vaximmutors to different vaccine types, formulations, and conditions reported in the other parts of the VIOLIN database. By collecting and analyzing the vaximmutors and their related vaccines and experimental conditions, we were able to identify new insights into the mechanisms of vaccine-induced immune responses.</p>
  </sec>
  <sec sec-type="methods" id="s2">
    <title>Methods</title>
    <sec>
      <title>System and Database Design</title>
      <p>The VaximmutorDB web application (<ext-link ext-link-type="uri" xlink:href="http://www.violinet.org/vaximmutordb">http://www.violinet.org/vaximmutordb</ext-link>) was supported by the Apache HTTP server hosted at two HP ProLiant DL380 G6 servers computers that run the RedHat Enterprise Linux operating system (release 5.8, <ext-link ext-link-type="uri" xlink:href="https://www.redhat.com/">https://www.redhat.com/</ext-link>). A MariaDB database (version 5.5.64, <ext-link ext-link-type="uri" xlink:href="https://mariadb.org/">https://mariadb.org/</ext-link>) server that stores data and a PHP web application server that presents HTML-based web pages for users to view in the browser are also installed at these two computers. The web page includes many functions such as vaximmutor data query and BLAST sequence similarity analysis. The development of these features was achieved using the PHP programming language (version 7.2.15, <ext-link ext-link-type="uri" xlink:href="https://www.php.net">https://www.php.net</ext-link>) and scripts that interact with the internal MariaDB relational database.</p>
    </sec>
    <sec>
      <title>Semi-Automatic Data Annotation, Submission, Review, and Approval</title>
      <p>A semi-automatic data curation pipeline was implemented in VaximmutorDB (<xref ref-type="fig" rid="F1">Figure 1</xref>). Specifically, a curator identified and manually annotated peer-reviewed articles from the PubMed literature database, and added to our internal web-based literature curation and analysis system (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). In terms of immune responses, only PubMed results were annotated in our database since VaximmutorDB focuses on the annotation and collection of experimentally verified vaccine immune factors (vaximmutors) reported in original peer-reviewed journal articles. Meanwhile, the general vaccine information has been extracted from many other resources such as FDA package inserts. The gene and protein sequences were obtained from the NCBI Gene and Protein databases. Immune factors associated with all types of vaccines such as live or killed vaccines or subunit vaccines are all within our scope of annotation. The VaximmutorDB data annotation has started since 2010. Vaximmutor-related contents in the database include the vaccine name, vaximmutor gene name, Gene ID, PubMed PMID, vaccination route, host responses, and protection level. Vaximmutor-induced host responses are annotated as text description. With a PubMed PMID, our system is able to automatically retrieve all related citation information. With an identified Gene ID, our internal script could automatically retrieve gene name, protein name, species, DNA and protein sequences. A customized BLAST search was also developed. The system also allows an annotator to submit data and invite reviewers to check, edit, and approve the submitted annotations. Only after the review and approval of a domain expert, information will be integrated and made available in the VaximmutorDB website for outside users to query and browse.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Overall system/architecture design. Vaximmutors are collected from manual curation of peer-reviewed articles available in PubMed. Gene names, NCBI Gene IDs, and gene fold changes were extracted and input into the VaximmutorDB. The NCBI Gene or Protein ID was used by a script that automatically extracts gene position, protein name, DNA sequence, and protein sequence from the NCBI Entrez Gene Database.</p>
        </caption>
        <graphic xlink:href="fimmu-12-639491-g0001"/>
      </fig>
    </sec>
    <sec>
      <title>Gene Ontology (GO) Enrichment Analysis</title>
      <p>Gene IDs for vaximmutors were extracted from the VaximmutorDB, and the GO enrichment analysis was conducted using the web-based DAVID bioinformatics service (<xref rid="B12" ref-type="bibr">12</xref>) and results were then downloaded. GO terms with False Discovery Rate (FDR) (<xref rid="B13" ref-type="bibr">13</xref>) adjusted <italic>p</italic>-value &lt; 0.05 were submitted to the GOFox program for visualization (<ext-link ext-link-type="uri" xlink:href="http://gofox.hegroup.org/">http://gofox.hegroup.org/</ext-link>).</p>
    </sec>
    <sec>
      <title>Reactome Pathway Analysis</title>
      <p>Pathway analysis was conducted using Reactome (<ext-link ext-link-type="uri" xlink:href="https://www.reactome.org">https://www.reactome.org</ext-link>) (<xref rid="B6" ref-type="bibr">6</xref>), the most comprehensive open source biological pathway knowledgebase. We used ReactomeFIViz (Version 8.0.0 with pathways released in December, 2019 from Reactome release 71), Rectome Cytoscape app, for pathway enrichment analysis after collecting vaximmutors for specific studies from the VaximmutorDB and mapping human Gene IDs to gene symbols (<xref ref-type="supplementary-material" rid="SM5">Supplementary File 1</xref>). The analysis results were explored from ReactomeFIViz for overlap analysis using R (<ext-link ext-link-type="uri" xlink:href="https://www.r-project.org">https://www.r-project.org</ext-link>). For Fisher's exact test, we used 1,769 for the number of total human pathways (Reactome release 71, disease pathways were excluded) and 20,490 for human protein coding genes based on reviewed UniProt records collected in the Reactome database. FDR adjusted <italic>p</italic>-values were calculated and applied for pathway enrichment analysis results. Pathways having FDR values &lt; 0.05 were selected as significant pathways.</p>
    </sec>
    <sec>
      <title>Two Use Case Studies</title>
      <p>To showcase the utilities of VaximmutorDB, two specific use cases were studied. One use case was to compare and analyze the similarities and differences of the vaximmutors derived from two studies of clinical human responses to the same type of yellow fever vaccine (YF-Vax) (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). Another use case is the comparative analysis of vaximmutors associated with live attenuated and killed inactivated influenza vaccines (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>).</p>
    </sec>
  </sec>
  <sec sec-type="results" id="s3">
    <title>Results</title>
    <sec>
      <title>VaximmutorDB Database Statistics</title>
      <p>VaximmutorDB currently stores 1,740 vaccine immune factors from 13 host species (e.g., human, mouse, and pig), annotated from over 200 peer-reviewed journal publications. The VaximmutorDB web query interface allows users to identify vaximmutors for specific hosts. For example, VaximmutorDB includes 1,691 human vaximmutors, 30 mouse vaximmutors, and 4 monkey vaximmutors.</p>
      <p>The vaximmutors stored in VaximmutorDB are triggered by 154 various types of vaccines for 46 pathogens. These vaccines cover various vaccine types such as live attenuated vaccines, killed inactivated vaccines, recombinant protein vaccines, DNA vaccines, and recombinant vector vaccines. The database architecture, and the contents and flows of our manually annotated data are illustrated in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p>
    </sec>
    <sec>
      <title>Top Vaximmutors Showing Most Influential Vaccine Immune Factors</title>
      <p><xref rid="T1" ref-type="table">Table 1</xref> lists the top 10 vaximmutors identified to be associated with most vaccines in VaximmutorDB (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). Among the top 10 vaximmutors are three antibodies (IgG, IgG2a and IgG1), two T helper type 1 (Th1) cytokines (IFN-γ and IL-2) (<xref rid="B18" ref-type="bibr">18</xref>), two T helper type 2 (Th2) cytokines (IL-4 and IL-6) (<xref rid="B18" ref-type="bibr">18</xref>), and three innate immune response factors (TNF-α, CASP-1, and TLR8). All these vaximmutors are up-regulated after some vaccination stimulation, except that TNF-α, IL-4, and TLR8 are sometimes down-regulated as well (<xref rid="T1" ref-type="table">Table 1</xref>). Note that our up- or down-regulated vaximmutor expression results only include those triggered by direct vaccination, and they do not include the responses stimulated by vaccination followed by virulent pathogen challenge. The up- or down-regulation of these vaximmutors indicate different types of vaccine immune responses as briefly introduced below.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Top 10 vaximmutors defined by number of associated vaccines.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Category</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Vaximmutor</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Host species</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>Associated vaccines</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>NCBI gene ID</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Description</bold>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Antibodies</td>
              <td valign="top" align="left" rowspan="1" colspan="1">IgG</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Mouse</td>
              <td valign="top" align="center" rowspan="1" colspan="1">37 (all up)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">16059</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Antibody</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">IgG2a</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Mouse</td>
              <td valign="top" align="center" rowspan="1" colspan="1">18 (all up)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">668478</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Antibody</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">IgG1</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Mouse</td>
              <td valign="top" align="center" rowspan="1" colspan="1">15 (all up)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">16017</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Antibody</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Th1 cytokines</td>
              <td valign="top" align="left" rowspan="1" colspan="1">IFN-gamma</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Mouse</td>
              <td valign="top" align="center" rowspan="1" colspan="1">47 (all up)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">15978</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Pro-inflammatory Th1 response</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">IL-2</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Mouse</td>
              <td valign="top" align="center" rowspan="1" colspan="1">8 (all up)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">16183</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Th1, T cell stimulation</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Th2 cytokines</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>IL-4</italic>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">Mouse</td>
              <td valign="top" align="center" rowspan="1" colspan="1">12 (8 up, 4 down)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">16189</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Th2, IgE production</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">More innate immune response factors</td>
              <td valign="top" align="left" rowspan="1" colspan="1">IL-6</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Mouse</td>
              <td valign="top" align="center" rowspan="1" colspan="1">8 (all up)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">16193</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Th1/Th2 differentiation</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">TNFα</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Mouse</td>
              <td valign="top" align="center" rowspan="1" colspan="1">11 (7 up, 4 down)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">21926</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Pro-inflammatory Th1 response</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">CASP-1</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Human</td>
              <td valign="top" align="center" rowspan="1" colspan="1">5 (all up)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">834</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Pro-inflammatory, pyroptosis</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">TLR8</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Human</td>
              <td valign="top" align="center" rowspan="1" colspan="1">5 (4 up, 1 up and down at different days)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">51311</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Adjuvant effect, NF-KB pathway activation, PAMP recognition</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Humoral antibody response is a critical vaccine-induced response. The 2nd−4th most common vaximmutors are IgG, IgG2a, and IgG1, which are antibodies produced by B cells. IgG antibodies have a high specific affinity for pathogen antigens. IgG antibodies are also involved in the secondary immune response and help to establish immunological memory. The presence of these antibodies highlights the significance of the antibodies in establishing a long-term immunological memory to fight infection. IgG2a and IgG1 are produced by antigen-specific B cells induced by Th1 and Th2 cells, respectively (<xref rid="B19" ref-type="bibr">19</xref>). As a result, IgG2a and IgG1 have been frequently used to test Th1 and Th2 responses (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>).</p>
      <p>Th1 and Th2 immune responses have been critical to vaccine responses. Th1 responses stimulate cell-mediated cytotoxic T lymphocyte (CTL) activity, and Th2 responses are critical to stimulate antibody responses. The induction of the Th1 response by vaccines is therefore important to the clearance of the corresponding intracellular pathogens from the host. Interferon gamma (IFN-γ), the most common vaximmutor found in our database, is a cytokine of the Th1 immune response, which promotes activation and production of macrophages and natural killer cells. IFN-γ enhances the production of IgG2a. As a pro-inflammatory cytokine, IFN-γ helps to destroy pathogens by increasing phagocytosis, forming granulomas, and promoting MHC II expression (<xref rid="B18" ref-type="bibr">18</xref>). IFN-γ also synergistically works with TNF-α (the fifth most common vaximmutor) to promote the Th1 response against pathogen infection. The roles of TNF-α also include maintaining granulomas, an important defense mechanism against mycobacteria (<xref rid="B22" ref-type="bibr">22</xref>). Interleukine-4 (IL-4), the 6th most common vaximmutor, is an important cytokine involved in activating Th2 cells. IL-4 promote B cell response and production of IgG1 and IgE antibodies (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). IL-4 can also be inhibitory to the Th1 response (<xref rid="B23" ref-type="bibr">23</xref>). IL-6 has multiple roles. It may function as a pro-inflammatory or an anti-inflammatory cytokine. IL-6 participates in acute phase, response, macrophage differentiation, and B cell maturation. IL-6 also controls the Th1/Th2 differentiation by promoting Th2 differentiation and inhibiting Th1 polarization (<xref rid="B24" ref-type="bibr">24</xref>).</p>
      <p>CASP-1 and TLR8, the two other innate immune response factors identified in our database, can also stimulate strong pro-inflammatory responses and are important to fight against various diseases (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). Like IFN-γ and TNF-α, Caspase-1 (CASP-1) also promotes proinflammatory responses. CASP-1 induces the secretion of the proinflammatory cytokines IL-1β and IL-18, and pyroptosis, a form of proinflammatory cell death induced by bacterial pathogens (<xref rid="B27" ref-type="bibr">27</xref>–<xref rid="B30" ref-type="bibr">30</xref>). The frequent finding of CASP-1 in VaximmutorDB suggests the importance of CASP-1 in protective vaccine immunity. Toll-like receptor 8 (TLR8) agonists are potent vaccine adjuvants, and the TLR8 bound human agonists induce the maturation of human myeloid dendritic cells (mDCs) and plasmacytoid DCs (pDCs) that link innate and adaptive immunity (<xref rid="B31" ref-type="bibr">31</xref>). Extending the traditional Th1 and Th2 cell dichotomy, the third distinct lineage of CD4 T helper cells called T helper 17 (Th17) cells have been discovered (<xref rid="B32" ref-type="bibr">32</xref>–<xref rid="B34" ref-type="bibr">34</xref>). Th17 cells produce effector molecules IL-17, IL-17F, IL-21, and IL-22. Th17 cells and their induced cytokines have been found critical for vaccine-induced memory immunity against a variety of pathogens, primarily at mucosal sites (<xref rid="B35" ref-type="bibr">35</xref>). VaximmutorDB includes IL-17 (<xref rid="B36" ref-type="bibr">36</xref>–<xref rid="B38" ref-type="bibr">38</xref>) and IL-17F (<xref rid="B39" ref-type="bibr">39</xref>) as vaximmutors; however, they are not ranked as high based on their associated vaccines.</p>
    </sec>
    <sec>
      <title>Enriched Vaccine Immune Responses Analyzed Using All Vaximmutors</title>
      <p>Our Gene Ontology (GO) enrichment analysis of all available human vaximmutors identified the most enriched GO biological process and cellular component terms (<xref ref-type="fig" rid="F2">Figure 2</xref>). As expected, both the innate and adaptive immune responses (both <italic>p</italic>-value &lt; 10<sup>−5</sup>) as well as antigen processing and presenting (adjusted <italic>p</italic>-value &lt; 0.05) were enriched (<xref ref-type="fig" rid="F2">Figure 2A</xref>). MyD88-dependent Toll-like receptor (<italic>p</italic>-value &lt; 0.001) and stimulatory C-type lectin receptor (<italic>p</italic>-value &lt; 0.05) signal pathways are identified to be significantly enriched. Cellular response to lipopolysaccharide is identified, suggesting the critical role of bacterial lipopolysaccharide to vaccine-induced immunity. It is unexpected to find the process of “SRP-dependent cotranslational protein targeting to membrane” in our analysis (<italic>p</italic>-value &lt; 10<sup>−5</sup>). The signal recognition particle (SRP) and its membrane-bound receptor (SR) deliver membrane proteins and secretory proteins to the endoplasmic reticulum (ER) membrane (<xref rid="B40" ref-type="bibr">40</xref>). The SRP pathway is a main mechanism that targets polypeptides in Gram-positive bacteria. In <italic>Streptococcus pyogenes</italic>, the SRP pathway is required for the secretion of a subset of virulence factors, the <italic>in vivo</italic> survival, and the pathogenesis of bacterium (<xref rid="B41" ref-type="bibr">41</xref>). Peptides loading on the MHC class I molecule occurs in the ER, suggesting that the transportation of antigens to ER is critical (<xref rid="B42" ref-type="bibr">42</xref>). It is possible that vaccine antigens undergo both the SRP pathway and antigen presentation pathway and there is an intricate interaction between the two pathways. In cellular components, we found the enriched MHC class II (<italic>p</italic>-value &lt; 0.05, but not class I) protein complex (<xref ref-type="fig" rid="F2">Figure 2B</xref>), suggesting that MHC class II protein complex is more frequently found than MHC class I protein complex in general vaccine immune responses. MHC class II molecules are normally found on professional antigen-presenting cells such as dendritic cells and macrophages, and are important in initiating immune responses. Many organelles, including melanosome, lysosome, extracellular exosome, and nucleoplasm were also enriched in our analysis (<xref ref-type="fig" rid="F2">Figure 2B</xref>).</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>GO enrichment analysis of all human vaximmutors. All available 1,675 human vaximmutors were extracted and analyzed using DAVID tool, and the enriched GO biological processes <bold>(A)</bold> and cellular components <bold>(B)</bold> were processed and visualized using GOfox. The <italic>p</italic>-value bar represented the color representation scheme of different adjusted <italic>p</italic>-value ranges. The cutoff was set as 0.05.</p>
        </caption>
        <graphic xlink:href="fimmu-12-639491-g0002"/>
      </fig>
    </sec>
    <sec>
      <title>Pathway-Based Analysis of Vaximmutors Uncovering Molecular Mechanisms of Vaccine Response</title>
      <p>The vaximmutors induced by influenza and yellow fever vaccines were extracted from the VaximmutorDB and specifically analyzed. By comparing their associated pathways, overlapping but different profiles were identified (<xref ref-type="fig" rid="F3">Figure 3</xref>). These use cases are detailed below.</p>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Reactome pathway enrichment analysis highlighting significant pathways of <bold>(A)</bold> FluMist (145 genes), <bold>(B)</bold> Fluarix (84 genes), <bold>(C)</bold> Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) (620 genes) and <bold>(D)</bold> Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>) (571 genes). The complexity of biomolecular pathways is organized by hierarchical groupings of the FoamTree (<ext-link ext-link-type="uri" xlink:href="https://carrotsearch.com/foamtree/">https://carrotsearch.com/foamtree/</ext-link>) and the color gradient highlights most to least significant pathways (<italic>p</italic>-value &lt; 0.05).</p>
        </caption>
        <graphic xlink:href="fimmu-12-639491-g0003"/>
      </fig>
      <sec>
        <title>Use Case 1. Differential Immune Response Profiles of Vaximmutors Associated With Live Attenuated and Killed Inactivated Influenza Vaccines</title>
        <p>Vaximmutors associated with influenza vaccines include 145 human genes induced by FluMist, a live attenuated influenza vaccine (LAIV) (<xref rid="B17" ref-type="bibr">17</xref>), and 84 human genes induced by Fluarix (<xref rid="B16" ref-type="bibr">16</xref>), a trivalent inactivated vaccine (TIV). These immune factors correlate with protection and have been compiled in this study. It is interesting that our previous ontology-based study found that LAIV is safer than TIV in terms of their association with severe adverse events (<xref rid="B43" ref-type="bibr">43</xref>). Note that the LAIV vaccination is not recommended for children and adults over the age of 49 years. Therefore, more comprehensive studies and comparisons are needed to compare the safety profiles between LAIV and TIV under specific conditions.</p>
        <p>Significant similarities and differences between FluMist and Fluarix-induced vaximmutors pathways were identified (<xref ref-type="fig" rid="F3">Figures 3A,B</xref>, <xref ref-type="supplementary-material" rid="SM6">Supplementary File 2</xref>). Both FluMist and Fluarix stimulated the signaling pathways of many interleukins (including IL-1, IL-4, IL-6, IL-13, IL-20, and IL-27), interferon signaling, MARK1 activation, neutrophil degranulation, and innate immunity (Supplementary File 2). These shared enriched immune responses appear to be crucial to the protection against influenza infection.</p>
        <p>Many unique profiles were stimulated by live attenuated vaccine FluMist and killed inactivated vaccine Fluarix. Overall FluMist stimulated a much wider response than Fluarix (<xref ref-type="fig" rid="F3">Figures 3A,B</xref> and <xref ref-type="supplementary-material" rid="SM1">Supplementary Figures 1</xref>, <xref ref-type="supplementary-material" rid="SM2">2</xref>). Particularly, FluMist stimulated statistically significantly enriched responses in the areas of cytokine signaling in immune system, signaling by receptor tyrosine kinases, death receptor signaling, and cellular responses to external stimuli (<xref ref-type="fig" rid="F3">Figure 3A</xref>). There are 10 Toll like receptors (TLRs) in humans that recognize various structurally conserved molecules from microbes. Interestingly, FluMist stimulated all types of signaling cascade pathways of TLRs except TLR1 with much lower <italic>p</italic>-values than Fluarix (Supplementary File 2). NOD1 and NOD2, two intracellular pattern recognition receptors, were also significantly induced by FluMist. FluMist also stimulated many important immune cytokines including TNF, and Interferon alpha/beta. In contrast, Fluarix stimulates many pathways such as those involved in protein metabolism, vesicle-mediated transport, and hemostatsis (<xref ref-type="fig" rid="F3">Figure 3B</xref> and <xref ref-type="supplementary-material" rid="SM2">Supplementary Figure 2</xref>). The immune responses stimulated by Fluarix focus on complement cascade and its regulation, and B cell receptor signaling (<xref ref-type="supplementary-material" rid="SM6">Supplementary File 2</xref>).</p>
      </sec>
      <sec>
        <title>Use Case 2. Common Vaccine Response Mechanisms Revealed by Pathway-Based Comparison Analysis of Two YF-Vax Vaccine Response Studies</title>
        <p>Live attenuated yellow fever virus vaccine YF-17D and its substrains (including YF-Vax) derived from the original 17D strain (<xref rid="B44" ref-type="bibr">44</xref>) have been widely used for vaccination, and the immune responses in vaccinated humans tend to be strong (<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>). YF-17D is an ideal vaccine model for protective immune mechanism studies (<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>). To uncover the molecular mechanisms underlying YF-17D responses, we conducted pathway analysis and compared significantly enriched pathways using vaximmutors collected in VaximmutorDB from two studies: Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>) and Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>).</p>
        <p>While significantly expressed genes from two studies differed, their pathway results appeared to be more conserved than the gene list difference. Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>) and Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) identified 571 and 620 differentially expressed genes in human subjects' immune response that were vaccinated with the same yellow fever vaccine YF-Vax, respectively (<xref ref-type="supplementary-material" rid="SM5">Supplementary File 1</xref>). Among these genes, 110 were shared, 461 unique in Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>), and 510 unique in Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) (<xref ref-type="fig" rid="F4">Figure 4</xref>). Though the two sets of vaximmutors are significantly overlapped (<italic>p</italic>-value &lt; 2.2E-16), the number of shared vaximmutors is low: 19% Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>) study and 18% for Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) studies (<xref ref-type="fig" rid="F4">Figure 4A</xref>). Meanwhile, we performed pathway enrichment analysis and compared the significant pathways using Reactome's ReactomeFIViz app. Our results identified more shared pathways than shared genes (<xref ref-type="fig" rid="F4">Figure 4</xref>, <xref ref-type="supplementary-material" rid="SM7">Supplementary File 3</xref>). Our results (<xref ref-type="supplementary-material" rid="SM7">Supplementary File 3</xref>) uncover 127 significant pathways for Scherer et al. study and 50 significant pathways for Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) study. Among these pathways, 38 are shared between these two studies (<italic>p</italic>-value &lt; 2.2E-16) (<xref ref-type="supplementary-material" rid="SM7">Supplementary File 3</xref>). Compared to gene-based overlap analysis results, pathway-based analysis results show much higher shared ratios: 30 and 76% for Scherer et al. study and Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) study, respectively. The similar pathway profiles shown up in <xref ref-type="fig" rid="F3">Figures 3C,D</xref> (<xref ref-type="supplementary-material" rid="SM3">Supplementary Figure 3</xref>) also confirmed the pattern.</p>
        <fig id="F4" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Gene and pathway level comparison between Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>) and Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>). Both studies analyzed YF-Vax-induced immune responses in vaccinated human subjects. The comparison between these two studies based on: <bold>(A)</bold> numbers of significant genes; <bold>(B)</bold> enriched Reactome pathways based on both unique and shared genes; and <bold>(C)</bold> enriched Reactome pathways based on only unique genes (Note that 110 genes in A were not included for this analysis). Even when no shared genes are analyzed, many pathways are shared as seen in <bold>(C)</bold>.</p>
          </caption>
          <graphic xlink:href="fimmu-12-639491-g0004"/>
        </fig>
        <p>To further provide evidence showing that pathway-based analysis is better to show common vaccine response mechanisms than using genes alone, we conducted another pathway enrichment and comparison analysis using vaximmutors that are not shared in these two studies. Reactome analysis tool produced 74 significant pathways for Scherer et al. study and 47 for Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) study (<xref ref-type="fig" rid="F4">Figure 4C</xref>, <xref ref-type="supplementary-material" rid="SM8">Supplementary File 4</xref>). Among these pathways, 28 are shared (<italic>p</italic>-value &lt; 2.2E-16), the majority of which are related to metabolisms of proteins and RNAs, implying a higher activity of synthesis of proteins during vaccine response. Interestingly all these 28 shared pathways (<xref ref-type="fig" rid="F4">Figure 4C</xref>) are included in 38 shared pathways (<xref ref-type="fig" rid="F4">Figure 4B</xref>) produced using all vaximmutors without removing shared ones, implying a significant portion of useful information are provided from these vaximmutors not shared by these two studies.</p>
        <p>Reactome provides biochemical reactions-based pathway diagrams based on the SBGN standard (<xref rid="B47" ref-type="bibr">47</xref>) to help users understand enrichment analysis results. For example, focusing on pathways annotated under Interferon Signaling, a sub-pathway of Cytokine Signaling in Immune System and a significant pathway for both studies, we found IFN α/β signaling showing greater involvement in Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) (Hits: 27/69, FDR = 4.33E-15) than in Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>) (Hits: 20/69, <italic>p</italic>-value = 3.10E-11) though it is a significant pathway for both studies. Investigating the detailed biochemical reaction-based pathway diagram for Interferon Alpha/Beta Signaling (<xref ref-type="fig" rid="F5">Figures 5A,B</xref>), we found that most of the vaximmutors from both studies are related to a reaction called “Expression of IFN-induced genes” (<ext-link ext-link-type="uri" xlink:href="https://reactome.org/PathwayBrowser/#/R-HSA-909733&amp;SEL=R-HSA-1015702">https://reactome.org/PathwayBrowser/#/R-HSA-909733&amp;SEL=R-HSA-1015702</ext-link>), presumably the reason why this pathway is a significantly enriched pathway for both studies, though the Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) study has more hits than the Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>) study. However, intriguingly, the Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>) study has also implied the involvement of USP18, which is not shown in the Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) study, while the Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) study has STAT1 that is not shown in the Scherer et al. study.</p>
        <fig id="F5" position="float">
          <label>Figure 5</label>
          <caption>
            <p>Reactome pathway enrichment analysis highlighting Interferon alpha/beta Signaling pathways found to be significant in both <bold>(A)</bold> Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) and <bold>(B)</bold> Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>). The pathway diagram is in the Systems Biology Graphical Notation (SBGN) (<xref rid="B47" ref-type="bibr">47</xref>) format. Results from both studies imply the stimulation of expression of IFN-induced genes though the Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) study shows more hit genes than the Scherer et al. study. Intriguingly, the Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) study implies STAT1, which is not shown in the Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>) study, while the Scherer study has USP18 that is not shared in the Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) study.</p>
          </caption>
          <graphic xlink:href="fimmu-12-639491-g0005"/>
        </fig>
      </sec>
    </sec>
    <sec>
      <title>VaximmutorDB Web Query and Data Integration</title>
      <p>The Vaximmutor data collected in VaximmutorDB are freely available for download via the website as described in the Methods section. The manually-curated and pre-computed VaximmutorDB data can be efficiently queried and visualized (<xref ref-type="fig" rid="F6">Figure 6</xref>). Specifically, the VaximmutorDB web query system allows querying of various vaximmutors, related vaccines, gene and protein details, and manually annotated host vaximmutor response information (<xref ref-type="fig" rid="F6">Figures 6A,B</xref>). Whenever possible, the website also provides the Vaccine Ontology (VO) IDs and links to the detailed ontology pages (<xref ref-type="fig" rid="F6">Figures 6C,D</xref>). The users can also perform pathway-enrichment analysis using the Reactome's analysis tool directly from this web site.</p>
      <fig id="F6" position="float">
        <label>Figure 6</label>
        <caption>
          <p>VaximmutorDB web query example. <bold>(A)</bold> Search VaximmutorDB for influenza virus (pathogen), human (host), and gene names containing “IFN.” <bold>(B)</bold> Three genes are found and each gene is associated with two influenza vaccines. <bold>(C)</bold> The detailed vaccine information and how the gene was regulated in vaccinated hosts are provided in another VaximmutorDB page. <bold>(D)</bold> A click of the VO ID leads to an Ontobee Ong et al. (<xref rid="B48" ref-type="bibr">48</xref>) web page showing the information about this vaccine. There are many links on different pages to useful information.</p>
        </caption>
        <graphic xlink:href="fimmu-12-639491-g0006"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s4">
    <title>Discussion</title>
    <p>The contribution of this paper is multiple. First, we for the first time introduce VaximmutorDB, a novel web-based database focusing on the manual annotation and analysis of vaccine immune factors named as vaximmutors. To our knowledge, VaximmutorDB is the first web-based database of such vaccine immune factors. A total of over 1,700 vaximmutors were collected and manually annotated. Second, our systematic analysis of vaximmutors identified many insights in terms of the mechanisms of vaccine-induced responses. Top 10 vaximmutors and GO enriched patterns with all the vaximmutors were identified and their contributions to vaccine protection analyzed. The different vaximmutor responses by two different types (live attenuated and killed inactivated) of influenza vaccines and one type yellow fever vaccine (i.e., YF-17D) but in different studies were also systematically analyzed and reported. The database query and data sharing format are also provided.</p>
    <p>Specific patterns have been identified from our analyses of all the collected Vaximmutors. For example, our top 10 vaximmutors identified IgG, IgG2a, and IgG1, and many Th1 and Th2 cytokines, which are critical to protective vaccine immune responses (<xref rid="T1" ref-type="table">Table 1</xref>). Pro-inflammatory factors, such as CASP-1, TNFα, and IFN-γ, are among the top 10 vaximmutors. Our GO enrichment analysis identified many enriched biological processes and cellular components (<xref ref-type="fig" rid="F2">Figure 2</xref>). In addition to generally known processes such as innate and adaptive immune responses, many uncommon processes such as “stimulatory C-type lectin receptor signaling pathway” and “SRP-dependent cotranslational protein targeting to membrane” are also found. C-type lectin receptors expressed by dendritic cells are critical to regulate the induction of signaling pathways that further regulate adaptive immune responses (<xref rid="B4" ref-type="bibr">4</xref>). Signal-recognition particle (SRP) is a cytosolic particle that transiently binds to the ER signal sequence in a nascent protein. SRP-dependent cotranslational proteins targeting to membrane appear to be important to viral immune responses (<xref rid="B49" ref-type="bibr">49</xref>). How these pathways are related to vaccine protection deserves further investigation.</p>
    <p>Vaccine-induced immune responses appear to differ given different types of vaccines (<xref ref-type="fig" rid="F3">Figure 3</xref>). Live attenuated (FluMist) and killed inactivated (Fluarix) appeared to induce overlapping host responses. While they shared enriched immune system responses, FluMist induced significant signal transduction responses (<xref ref-type="fig" rid="F3">Figure 3A</xref>), and Fluarix induced significant metabolism of protein responses (<xref ref-type="fig" rid="F3">Figure 3B</xref>). These results suggested that the live attenuated influenza vaccine underwent many signal transduction processes after vaccinated, and the killed inactivated vaccine stimulated metabolic processes to digest the killed viruses. The signal transduction from LAIV and metabolic process from TIV might significantly impact the vaccine safety and efficacy. The two Yellow Fever vaccine studies appeared to show very similar vaccine-induced responses in the vaccines (<xref ref-type="fig" rid="F3">Figures 3C,D</xref>). Strong immune system responses were stimulated. Different from the live attenuated influenza vaccine FluMist, the Yellow Fever live attenuated vaccine stimulated strong metabolism responses similar to the killed vaccine Fluarix. Interestingly, the Yellow Fever vaccine and Fluarix both stimulated “SRP-dependent cotranslational protein targeting to membrane” (<italic>p</italic>-value &lt; 0.001) (<xref ref-type="supplementary-material" rid="SM6">Supplementary Files 2</xref>, <xref ref-type="supplementary-material" rid="SM7">3</xref>), which were consistent with the observation found with all the vaximmutors (see above). Therefore, the vaccine immune patterns can be quite different depending on the vaccine and pathogen types. Note that some specific responses, such as interferon signaling, appeared to be shared by all influenza and Yellow Fever vaccines. More detailed studies on the similarities and differences are required to understand the underlying causal mechanisms.</p>
    <p>More exploration is needed to understand the interesting observation that killed inactivated Fluarix (<xref ref-type="fig" rid="F3">Figure 3B</xref>) and live attenuated YF-Vax (<xref ref-type="fig" rid="F3">Figures 3C,D</xref>), but not live attenuated FluMist (<xref ref-type="fig" rid="F3">Figure 3A</xref>), simulate significant responses in the metabolism of proteins. The results suggest that killed inactivated and live attenuated vaccine antigens are able to induce similar responses such as the metabolism responses, which is likely significantly influenced by their associated vaccine adjuvants and immune stimulators. In addition, the route of vaccination may play a major role. YF-Vax is administered through subcutaneous rote, and Fluarix through intramuscular injection. While the live/killed phenotype and pathogen type of vaccines differ, the route of vaccination causes more confusion for the final outcome analysis.</p>
    <p>Our Yellow Fever vaccine study showed that the administration of the same vaccine can result in different outcomes as identified in the two different high throughput studies. In our previous study (<xref rid="B50" ref-type="bibr">50</xref>), we applied the community-based Ontology of Biological and Clinical Statistics (OBCS) (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>) and Vaccine Ontology (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>) to study how different variables could change the identification of different vaccine immune factors in three yellow fever vaccine studies (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B54" ref-type="bibr">54</xref>). Our ontology-based meta-analysis of the variables identified over 20 variables whose values differed across these three different studies (<xref rid="B50" ref-type="bibr">50</xref>). Examples of these variables include different human subjects, sample preparation, RNA preparation, microarray chip type, raw data process software, and analysis settings. The differences in experimental conditions might have caused the different vaccine immune response studies.</p>
    <p>Meanwhile, our current study found that although the gene lists differ greatly from two different studies, the enriched pathways from these studies showed greater similarities (<xref ref-type="fig" rid="F4">Figure 4</xref>). It appears that although different genes were up- or down-regulated given different conditions, these genes participated in the similar set of pathways. In addition to the usage of the manually annotated VaximmutorDB knowledge, a previous direct analysis of raw OMICS data from different studies also resulted in the same conclusion (i.e., more shared pathways than shared gene lists) (<xref rid="B55" ref-type="bibr">55</xref>). Therefore, it is important to map genes to pathways and conduct pathway-based analysis and visualization of vaximmutors. Reactome is an important source for pathway analysis. Our results indicate that vaximmutors collected in VaximmutorDB combined with Reactome's multi-scale pathway perspectives facilitate functional analysis, allowing researchers to elucidate overarching molecular mechanisms within shared pathways that would not be possible by looking at vaximmutors alone.</p>
    <p>More vaximmutor-related research is needed to further understand the vaccine-induced immune mechanisms. Since we now know the different vaccine immune results given different experimental factors, we may be able to find more about the close relations among vaccines, vaximmutors, and pathways. It is important to identify specific vaximmutor gene markers that correlate with protection and identify vaccine-specific pathway patterns. More data, such as the high throughput data from the ImmPort immunology database and analysis portal (<ext-link ext-link-type="uri" xlink:href="https://ImmPort.niaid.nih.gov/">https://ImmPort.niaid.nih.gov/</ext-link>) (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>), can be systematically analyzed for such investigations. Ontologies such as OBCS, VO, Vaccine Investigation Ontology (VIO) (<xref rid="B55" ref-type="bibr">55</xref>), and Cell Ontology (<xref rid="B58" ref-type="bibr">58</xref>) can be used to standardize the data for efficient secondary data analyses. The gene expression results can be from transcriptomical or proteomic analysis. It would be ideal to differentiate different analyses, and ontology can support the standard representation and classification. The ontology-based high throughput gene expression data annotation and analyses are expected to further enhance our understanding of the vaccine immune mechanisms.</p>
    <p>The VaximmutorDB database will undergo continuous extension and analysis. We will keep adding more vaximmutors and associate them with more vaccines and associated information. We are also in the process of linking and integrating various vaximmutors to existing databases such as ImmPort portal and Reactome pathway database. The VaximmutorDB will include any relevant data on newer vaccines aimed at targeting COVID-19. It will analyze the immune responses elicited by the new COVID vaccines and compare them to the immune response of past vaccines.</p>
    <p>In conclusion, VaximmutorDB is the first web-based database of vaccine immune factors named vaximmutors. A total of over 1,700 vaximmutors from 13 host species (e.g., human, mouse, and pig) were collected, manually annotated, and further analyzed using bioinformatics approaches. Top 10 vaximmutors and the enriched patterns with all the vaximmutors were identified. Overlapping and differential gene lists and enriched pathways induced by live attenuated and killed inactivated influenza vaccines and yellow fever vaccines were identified and systematically analyzed. User-friendly database query and standard data sharing formats are provided. VaximmutorDB provides a powerful platform for annotation, standardization, storage, and analysis of vaccine immune factors, leading to the better understanding of the fundamental protective vaccine immunity.</p>
  </sec>
  <sec sec-type="data-availability" id="s5">
    <title>Data Availability Statement</title>
    <p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.</p>
  </sec>
  <sec id="s6">
    <title>Author Contributions</title>
    <p>KB, PS, JO, and RR collected and annotated data. EO, NS, AH, TB, and FL performed bioinformatics data. EO, BZ, and ZX generated the website. AM, JZ, and YH provide domain expert data interpretation. GW and YH contributed to the study design. KB, EO, NS, GW, and YH wrote the manuscript. All authors performed result interpretation, discussed, and reviewed the manuscript.</p>
  </sec>
  <sec sec-type="COI-statement" id="conf1">
    <title>Conflict of Interest</title>
    <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
</body>
<back>
  <fn-group>
    <fn fn-type="financial-disclosure">
      <p><bold>Funding.</bold> This project was supported by NIH NIAID grants 1UH2AI132931 and 1R01AI081062, and an NHGRI grant U41HG003751. JO, KB, and PS are supported by the Undergraduate Research Opportunity Program (UROP) at the University of Michigan.</p>
    </fn>
  </fn-group>
  <sec sec-type="supplementary-material" id="s7">
    <title>Supplementary Material</title>
    <p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2021.639491/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2021.639491/full#supplementary-material</ext-link></p>
    <supplementary-material content-type="local-data" id="SM1">
      <label>Supplementary Figure 1</label>
      <caption>
        <p>More detailed results of the Reactome pathway enrichment analysis highlighting significant pathways of FluMist (145 genes). The complexity of biomolecular pathways is organized by hierarchical groupings of the FoamTree (<ext-link ext-link-type="uri" xlink:href="https://carrotsearch.com/foamtree/">https://carrotsearch.com/foamtree/</ext-link>) and the color gradient highlights most to least significant pathways (<italic>p</italic>-value &lt; 0.05).</p>
      </caption>
      <media xlink:href="Image_1.PNG">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM2">
      <label>Supplementary Figure 2</label>
      <caption>
        <p>More detailed results of the Reactome pathway enrichment analysis highlighting significant pathways of Fluarix (84 genes). The complexity of biomolecular pathways is organized by hierarchical groupings of the FoamTree (<ext-link ext-link-type="uri" xlink:href="https://carrotsearch.com/foamtree/">https://carrotsearch.com/foamtree/</ext-link>) and the color gradient highlights most to least significant pathways (<italic>p</italic>-value &lt; 0.05).</p>
      </caption>
      <media xlink:href="Image_2.PNG">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM3">
      <label>Supplementary Figure 3</label>
      <caption>
        <p>More detailed results of the Reactome pathway enrichment analysis highlighting significant pathways induced by YF-Vax-induced immune factors as identified in Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) (620 genes). The complexity of biomolecular pathways is organized by hierarchical groupings of the FoamTree (<ext-link ext-link-type="uri" xlink:href="https://carrotsearch.com/foamtree/">https://carrotsearch.com/foamtree/</ext-link>) and the color gradient highlights most to least significant pathways (<italic>p</italic>-value &lt; 0.05).</p>
      </caption>
      <media xlink:href="Image_3.PNG">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM4">
      <label>Supplementary Figure 4</label>
      <caption>
        <p>More detailed results of the Reactome pathway enrichment analysis highlighting significant pathways induced by YF-Vax-induced immune factors as identified in Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>) (571 genes). The complexity of biomolecular pathways is organized by hierarchical groupings of the FoamTree (<ext-link ext-link-type="uri" xlink:href="https://carrotsearch.com/foamtree/">https://carrotsearch.com/foamtree/</ext-link>) and the color gradient highlights most to least significant pathways (<italic>p</italic>-value &lt; 0.05).</p>
      </caption>
      <media xlink:href="Image_4.PNG">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM5">
      <label>Supplementary File 1</label>
      <caption>
        <p>Specific gene lists identified for four vaccine immune factor studies: FluMist (145 genes), FluMist (145 genes), Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) (620 genes), and Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>) (571 genes).</p>
      </caption>
      <media xlink:href="Table_1.XLSX">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM6">
      <label>Supplementary File 2</label>
      <caption>
        <p>Significantly regulated Reactome pathways enriched by Flumist-induced vaximmutors, Fluarix-induced vaximmutors, and the shared pathways by both Flumist- and Fluraix-induced vaximmutors.</p>
      </caption>
      <media xlink:href="Table_2.XLSX">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM7">
      <label>Supplementary File 3</label>
      <caption>
        <p>Significantly regulated Reactome pathways enriched by vaximmutors found in Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) (620 genes), Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>) (571 genes), and shared by both studies.</p>
      </caption>
      <media xlink:href="Table_3.XLSX">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM8">
      <label>Supplementary File 4</label>
      <caption>
        <p>Significantly regulated Reactome pathways enriched by vaximmutors found vaximmutors that are not shared in these two studies Gaucher et al. (<xref rid="B15" ref-type="bibr">15</xref>) and Scherer et al. (<xref rid="B14" ref-type="bibr">14</xref>).</p>
      </caption>
      <media xlink:href="Table_4.XLSX">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulendran</surname><given-names>B</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name></person-group>. <article-title>Immunological mechanisms of vaccination</article-title>. <source>Nat Immunol.</source> (<year>2011</year>) <volume>12</volume>:<fpage>509</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2039</pub-id><pub-id pub-id-type="pmid">21739679</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>H</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group>. <article-title>Pathogen recognition by the innate immune system</article-title>. <source>Int Rev Immunol.</source> (<year>2011</year>) <volume>30</volume>:<fpage>16</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.3109/08830185.2010.529976</pub-id><?supplied-pmid 22960101?><pub-id pub-id-type="pmid">21235323</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group>. <article-title>The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors</article-title>. <source>Nat Immunol.</source> (<year>2010</year>) <volume>11</volume>:<fpage>373</fpage>. <pub-id pub-id-type="doi">10.1038/ni.1863</pub-id><?supplied-pmid 20404851?><pub-id pub-id-type="pmid">20404851</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geijtenbeek</surname><given-names>TB</given-names></name><name><surname>Gringhuis</surname><given-names>SI</given-names></name></person-group>. <article-title>Signalling through C-type lectin receptors: shaping immune responses</article-title>. <source>Nat Rev Immunol.</source> (<year>2009</year>) <volume>9</volume>:<fpage>465</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1038/nri2569</pub-id><?supplied-pmid 19521399?><pub-id pub-id-type="pmid">19521399</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkins</surname><given-names>C</given-names></name><name><surname>Gale</surname><given-names>Jr</given-names></name></person-group>. <article-title>M. Recognition of viruses by cytoplasmic sensors</article-title>. <source>Curr Opin Immunol.</source> (<year>2010</year>) <volume>22</volume>:<fpage>41</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2009.12.003</pub-id><?supplied-pmid 20061127?><pub-id pub-id-type="pmid">20061127</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jassal</surname><given-names>B</given-names></name><name><surname>Matthews</surname><given-names>L</given-names></name><name><surname>Viteri</surname><given-names>G</given-names></name><name><surname>Gong</surname><given-names>C</given-names></name><name><surname>Lorente</surname><given-names>P</given-names></name><name><surname>Fabregat</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The reactome pathway knowledgebase</article-title>. <source>Nucleic Acids Res</source>. (<year>2020</year>) <volume>48</volume>:<fpage>D498</fpage>–<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkz1031</pub-id><pub-id pub-id-type="pmid">31691815</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Racz</surname><given-names>R</given-names></name><name><surname>Chung</surname><given-names>M</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group>. <article-title>Systematic annotation and analysis of “virmugens” - virulence factors whose mutants can be used as live attenuated vaccines</article-title>. <source>Vaccine.</source> (<year>2013</year>) <volume>31</volume>:<fpage>797</fpage>–<lpage>805</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.11.066</pub-id><?supplied-pmid 23219434?><pub-id pub-id-type="pmid">23219434</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Medical Advisory Committee of the Immune Deficiency F Shearer WT Fleisher TA Buckley RH Ballas Z Ballow M </collab></person-group>. <article-title>Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts</article-title>. <source>J Allergy Clin Immunol.</source> (<year>2014</year>) <volume>133</volume>:<fpage>961</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2013.11.043</pub-id><pub-id pub-id-type="pmid">24582311</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>P</given-names></name><name><surname>Curtis</surname><given-names>N</given-names></name></person-group>. <article-title>Factors that influence the immune response to vaccination</article-title>. <source>Clin Microbiol Rev.</source> (<year>2019</year>) <volume>32</volume>:<fpage>18</fpage>. <pub-id pub-id-type="doi">10.1128/CMR.00084-18</pub-id><?supplied-pmid 30867162?><pub-id pub-id-type="pmid">30867162</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Todd</surname><given-names>T</given-names></name><name><surname>Ku</surname><given-names>KP</given-names></name><name><surname>Kovacic</surname><given-names>BL</given-names></name><name><surname>Larson</surname><given-names>CB</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>VIOLIN: vaccine investigation and online information network</article-title>. <source>Nucleic Acids Res.</source> (<year>2008</year>) <volume>36</volume>:<fpage>D923</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkm1039</pub-id><?supplied-pmid 18025042?><pub-id pub-id-type="pmid">18025042</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Racz</surname><given-names>R</given-names></name><name><surname>Sayers</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Todd</surname><given-names>T</given-names></name><name><surname>Hur</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Updates on the web-based VIOLIN vaccine database and analysis system</article-title>. <source>Nucleic Acids Res.</source> (<year>2014</year>) <volume>42</volume>:<fpage>D1124</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1133</pub-id><?supplied-pmid 24259431?><pub-id pub-id-type="pmid">24259431</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Huang</surname><given-names>W</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group>. <article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>. <source>Nat Protoc</source>. (<year>2009</year>) <volume>4</volume>:<fpage>44</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id><?supplied-pmid 19131956?><pub-id pub-id-type="pmid">19131956</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group>. <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J R Stat Soc.</source> (<year>1995</year>) <volume>57</volume>:<fpage>289</fpage>–<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherer</surname><given-names>CA</given-names></name><name><surname>Magness</surname><given-names>CL</given-names></name><name><surname>Steiger</surname><given-names>KV</given-names></name><name><surname>Poitinger</surname><given-names>ND</given-names></name><name><surname>Caputo</surname><given-names>CM</given-names></name><name><surname>Miner</surname><given-names>DG</given-names></name><etal/></person-group>. <article-title>Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infections</article-title>. <source>Vaccine.</source> (<year>2007</year>) <volume>25</volume>:<fpage>6458</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2007.06.035</pub-id><?supplied-pmid 17651872?><pub-id pub-id-type="pmid">17651872</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaucher</surname><given-names>D</given-names></name><name><surname>Therrien</surname><given-names>R</given-names></name><name><surname>Kettaf</surname><given-names>N</given-names></name><name><surname>Angermann</surname><given-names>BR</given-names></name><name><surname>Boucher</surname><given-names>G</given-names></name><name><surname>Filali-Mouhim</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses</article-title>. <source>J Exp Med.</source> (<year>2008</year>) <volume>205</volume>:<fpage>3119</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20082292</pub-id><?supplied-pmid 19047440?><pub-id pub-id-type="pmid">19047440</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curran</surname><given-names>MP</given-names></name><name><surname>Leroux-Roels</surname><given-names>I</given-names></name></person-group>. <article-title>Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly</article-title>. <source>Drugs.</source> (<year>2010</year>) <volume>70</volume>:<fpage>1519</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.2165/11205020-000000000-00000</pub-id><?supplied-pmid 20687619?><pub-id pub-id-type="pmid">20687619</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>NJ</given-names></name><name><surname>Curran</surname><given-names>MP</given-names></name></person-group>. <article-title>Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults</article-title>. <source>Drugs.</source> (<year>2011</year>) <volume>71</volume>:<fpage>1591</fpage>–<lpage>622</lpage>. <pub-id pub-id-type="doi">10.2165/11206860-000000000-00000</pub-id><?supplied-pmid 21861544?><pub-id pub-id-type="pmid">21861544</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>A</given-names></name></person-group>. <article-title>Th1 and Th2 responses: what are they?</article-title><source>BMJ.</source> (<year>2000</year>) <volume>321</volume>:<fpage>424</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.321.7258.424</pub-id><?supplied-pmid 10938051?><pub-id pub-id-type="pmid">10938051</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>TL</given-names></name><name><surname>Bossie</surname><given-names>A</given-names></name><name><surname>Sanders</surname><given-names>VM</given-names></name><name><surname>Fernandez-Botran</surname><given-names>R</given-names></name><name><surname>Coffman</surname><given-names>RL</given-names></name><name><surname>Mosmann</surname><given-names>TR</given-names></name><etal/></person-group>. <article-title>Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells</article-title>. <source>Nature.</source> (<year>1988</year>) <volume>334</volume>:<fpage>255</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/334255a0</pub-id><?supplied-pmid 2456466?><pub-id pub-id-type="pmid">2456466</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vemulapalli</surname><given-names>R</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Boyle</surname><given-names>SM</given-names></name><name><surname>Sriranganathan</surname><given-names>N</given-names></name><name><surname>Schurig</surname><given-names>GG</given-names></name></person-group>. <article-title>Brucella abortus strain RB51 as a vector for heterologous protein expression and induction of specific Th1 type immune responses</article-title>. <source>Infect Immun.</source> (<year>2000</year>) <volume>68</volume>:<fpage>3290</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.68.6.3290-3296.2000</pub-id><?supplied-pmid 10816476?><pub-id pub-id-type="pmid">10816476</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vemulapalli</surname><given-names>R</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Buccolo</surname><given-names>LS</given-names></name><name><surname>Boyle</surname><given-names>SM</given-names></name><name><surname>Sriranganathan</surname><given-names>N</given-names></name><name><surname>Schurig</surname><given-names>GG</given-names></name></person-group>. <article-title>Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation</article-title>. <source>Infect Immun.</source> (<year>2000</year>) <volume>68</volume>:<fpage>3927</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.68.7.3927-3932.2000</pub-id><?supplied-pmid 10858205?><pub-id pub-id-type="pmid">10858205</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorhoi</surname><given-names>A</given-names></name><name><surname>Kaufmann</surname><given-names>SH</given-names></name></person-group>. <article-title>Tumor necrosis factor alpha in mycobacterial infection</article-title>. <source>Semin Immunol.</source> (<year>2014</year>) <volume>26</volume>:<fpage>203</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.smim.2014.04.003</pub-id><pub-id pub-id-type="pmid">24819298</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paludan</surname><given-names>SR</given-names></name></person-group>. <article-title>Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship</article-title>. <source>Scand J Immunol.</source> (<year>1998</year>) <volume>48</volume>:<fpage>459</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-3083.1998.00435.x</pub-id><?supplied-pmid 9822252?><pub-id pub-id-type="pmid">9822252</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diehl</surname><given-names>S</given-names></name><name><surname>Rincon</surname><given-names>M</given-names></name></person-group>. <article-title>The two faces of IL-6 on Th1/Th2 differentiation</article-title>. <source>Mol Immunol.</source> (<year>2002</year>) <volume>39</volume>:<fpage>531</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S0161-5890(02)00210-9</pub-id><?supplied-pmid 12431386?><pub-id pub-id-type="pmid">12431386</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowling</surname><given-names>DJ</given-names></name></person-group>. <article-title>Recent advances in the discovery and delivery of TLR7/8 agonists as vaccine adjuvants</article-title>. <source>Immunohorizons.</source> (<year>2018</year>) <volume>2</volume>:<fpage>185</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.4049/immunohorizons.1700063</pub-id><?supplied-pmid 31022686?><pub-id pub-id-type="pmid">31022686</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mcnair</surname><given-names>NN</given-names></name><name><surname>Bedi</surname><given-names>C</given-names></name><name><surname>Shayakhmetov</surname><given-names>DM</given-names></name><name><surname>Arrowood</surname><given-names>MJ</given-names></name><name><surname>Mead</surname><given-names>JR</given-names></name></person-group>. <article-title>Inflammasome components caspase-1 and adaptor protein apoptosis-associated speck-like proteins are important in resistance to Cryptosporidium parvum</article-title>. <source>Microbes Infect.</source> (<year>2018</year>) <volume>20</volume>:<fpage>369</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2018.04.006</pub-id><?supplied-pmid 29842985?><pub-id pub-id-type="pmid">29842985</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>MA</given-names></name><name><surname>Cookson</surname><given-names>BT</given-names></name></person-group>. <article-title>Salmonella induces macrophage death by caspase-1-dependent necrosis</article-title>. <source>Mol Microbiol.</source> (<year>2000</year>) <volume>38</volume>:<fpage>31</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2958.2000.02103.x</pub-id><?supplied-pmid 11029688?><pub-id pub-id-type="pmid">11029688</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sansonetti</surname><given-names>PJ</given-names></name><name><surname>Phalipon</surname><given-names>A</given-names></name><name><surname>Arondel</surname><given-names>J</given-names></name><name><surname>Thirumalai</surname><given-names>K</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation</article-title>. <source>Immunity.</source> (<year>2000</year>) <volume>12</volume>:<fpage>581</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/S1074-7613(00)80209-5</pub-id><?supplied-pmid 10843390?><pub-id pub-id-type="pmid">10843390</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bronner</surname><given-names>DN</given-names></name><name><surname>O'riordan</surname><given-names>MX</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group>. <article-title>Caspase-2 mediates a Brucella abortus RB51-induced hybrid cell death having features of apoptosis and pyroptosis</article-title>. <source>Front Cell Infect Microbiol.</source> (<year>2013</year>) <volume>3</volume>:<fpage>83</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2013.00083</pub-id><?supplied-pmid 24350060?><pub-id pub-id-type="pmid">24350060</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bronner</surname><given-names>DN</given-names></name><name><surname>Abuaita</surname><given-names>BH</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Nunez</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Endoplasmic reticulum stress activates the inflammasome via NLRP3- and caspase-2-driven mitochondrial damage</article-title>. <source>Immunity.</source> (<year>2015</year>) <volume>43</volume>:<fpage>451</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2015.08.008</pub-id><?supplied-pmid 26341399?><pub-id pub-id-type="pmid">26341399</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>AJ</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Bazin</surname><given-names>HG</given-names></name><name><surname>St-Jean</surname><given-names>JR</given-names></name><name><surname>Larocque</surname><given-names>D</given-names></name><name><surname>Evans</surname><given-names>JT</given-names></name><etal/></person-group>. <article-title>Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants</article-title>. <source>Vaccine.</source> (<year>2016</year>) <volume>34</volume>:<fpage>4304</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.06.080</pub-id><?supplied-pmid 27402566?><pub-id pub-id-type="pmid">27402566</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrington</surname><given-names>LE</given-names></name><name><surname>Hatton</surname><given-names>RD</given-names></name><name><surname>Mangan</surname><given-names>PR</given-names></name><name><surname>Turner</surname><given-names>H</given-names></name><name><surname>Murphy</surname><given-names>TL</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages</article-title>. <source>Nat Immunol.</source> (<year>2005</year>) <volume>6</volume>:<fpage>1123</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1038/ni1254</pub-id><?supplied-pmid 16200070?><pub-id pub-id-type="pmid">16200070</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langrish</surname><given-names>CL</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Blumenschein</surname><given-names>WM</given-names></name><name><surname>Mattson</surname><given-names>J</given-names></name><name><surname>Basham</surname><given-names>B</given-names></name><name><surname>Sedgwick</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>IL-23 drives a pathogenic T cell population that induces autoimmune inflammation</article-title>. <source>J Exp Med.</source> (<year>2005</year>) <volume>201</volume>:<fpage>233</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20041257</pub-id><?supplied-pmid 15657292?><pub-id pub-id-type="pmid">15657292</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>XO</given-names></name><name><surname>Chang</surname><given-names>SH</given-names></name><name><surname>Nurieva</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><etal/></person-group>. <article-title>A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17</article-title>. <source>Nat Immunol.</source> (<year>2005</year>) <volume>6</volume>:<fpage>1133</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1038/ni1261</pub-id><pub-id pub-id-type="pmid">16200068</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Slight</surname><given-names>SR</given-names></name><name><surname>Khader</surname><given-names>SA</given-names></name></person-group>. <article-title>Th17 cytokines and vaccine-induced immunity</article-title>. <source>Semin Immunopathol.</source> (<year>2010</year>) <volume>32</volume>:<fpage>79</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1007/s00281-009-0191-2</pub-id><?supplied-pmid 20112107?><pub-id pub-id-type="pmid">20112107</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mcneal</surname><given-names>MM</given-names></name><name><surname>Basu</surname><given-names>M</given-names></name><name><surname>Bean</surname><given-names>JA</given-names></name><name><surname>Clements</surname><given-names>JD</given-names></name><name><surname>Lycke</surname><given-names>NY</given-names></name><name><surname>Ramne</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge</article-title>. <source>Vaccine.</source> (<year>2007</year>) <volume>25</volume>:<fpage>6224</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2007.05.065</pub-id><?supplied-pmid 17629371?><pub-id pub-id-type="pmid">17629371</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alteri</surname><given-names>CJ</given-names></name><name><surname>Hagan</surname><given-names>EC</given-names></name><name><surname>Sivick</surname><given-names>KE</given-names></name><name><surname>Smith</surname><given-names>SN</given-names></name><name><surname>Mobley</surname><given-names>HL</given-names></name></person-group>. <article-title>Mucosal immunization with iron receptor antigens protects against urinary tract infection</article-title>. <source>PLoS Pathog.</source> (<year>2009</year>) <volume>5</volume>:<fpage>e1000586</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1000586</pub-id><?supplied-pmid 19806177?><pub-id pub-id-type="pmid">19806177</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piao</surname><given-names>HH</given-names></name><name><surname>Tam</surname><given-names>VT</given-names></name><name><surname>Na</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Ryu</surname><given-names>PY</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><etal/></person-group>. <article-title>Immunological responses induced by asd and wzy/asd mutant strains of Salmonella enterica serovar Typhimurium in BALB/c mice</article-title>. <source>J Microbiol.</source> (<year>2010</year>) <volume>48</volume>:<fpage>486</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1007/s12275-010-0023-z</pub-id><?supplied-pmid 20799091?><pub-id pub-id-type="pmid">20799091</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolibab</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Derrick</surname><given-names>SC</given-names></name><name><surname>Waldmann</surname><given-names>TA</given-names></name><name><surname>Perera</surname><given-names>LP</given-names></name><name><surname>Morris</surname><given-names>SL</given-names></name></person-group>. <article-title>Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant</article-title>. <source>Clin Vaccine Immunol.</source> (<year>2010</year>) <volume>17</volume>:<fpage>793</fpage>–<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00006-10</pub-id><?supplied-pmid 20357059?><pub-id pub-id-type="pmid">20357059</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elvekrog</surname><given-names>MM</given-names></name><name><surname>Walter</surname><given-names>P</given-names></name></person-group>. <article-title>Dynamics of co-translational protein targeting</article-title>. <source>Curr Opin Chem Biol.</source> (<year>2015</year>) <volume>29</volume>:<fpage>79</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbpa.2015.09.016</pub-id><pub-id pub-id-type="pmid">26517565</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosch</surname><given-names>JW</given-names></name><name><surname>Vega</surname><given-names>LA</given-names></name><name><surname>Beyer</surname><given-names>JM</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Caparon</surname><given-names>MG</given-names></name></person-group>. <article-title>The signal recognition particle pathway is required for virulence in Streptococcus pyogenes</article-title>. <source>Infect Immun.</source> (<year>2008</year>) <volume>76</volume>:<fpage>2612</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00239-07</pub-id><?supplied-pmid 18411293?><pub-id pub-id-type="pmid">18411293</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sher</surname><given-names>YP</given-names></name><name><surname>Lin</surname><given-names>SI</given-names></name><name><surname>Chai</surname><given-names>KM</given-names></name><name><surname>Chen</surname><given-names>IH</given-names></name><name><surname>Liu</surname><given-names>SJ</given-names></name></person-group>. <article-title>Endoplasmic reticulum-targeting sequence enhanced the cellular immunity of a tumor-associated antigen L6-based DNA vaccine</article-title>. <source>Am J Cancer Res.</source> (<year>2019</year>) <volume>9</volume>:<fpage>2028</fpage>–<lpage>36</lpage>.<?supplied-pmid 31598403?><pub-id pub-id-type="pmid">31598403</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarntivijai</surname><given-names>S</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Shedden</surname><given-names>KA</given-names></name><name><surname>Markel</surname><given-names>H</given-names></name><name><surname>Omenn</surname><given-names>GS</given-names></name><name><surname>Athey</surname><given-names>BD</given-names></name><etal/></person-group>. <article-title>Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines</article-title>. <source>PLoS ONE.</source> (<year>2012</year>) <volume>7</volume>:<fpage>e49941</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0049941</pub-id><?supplied-pmid 23209624?><pub-id pub-id-type="pmid">23209624</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>CL</given-names></name><name><surname>Ryman</surname><given-names>KD</given-names></name></person-group>. <article-title>Yellow fever: a reemerging threat</article-title>. <source>Clin Lab Med.</source> (<year>2010</year>) <volume>30</volume>:<fpage>237</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.cll.2010.01.001</pub-id><pub-id pub-id-type="pmid">20513550</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roukens</surname><given-names>AH</given-names></name><name><surname>Visser</surname><given-names>LG</given-names></name></person-group>. <article-title>Yellow fever vaccine: past, present and future</article-title>. <source>Expert Opin Biol Ther.</source> (<year>2008</year>) <volume>8</volume>:<fpage>1787</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1517/14712598.8.11.1787</pub-id><?supplied-pmid 18847312?><pub-id pub-id-type="pmid">18847312</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulendran</surname><given-names>B</given-names></name></person-group>. <article-title>Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology</article-title>. <source>Nat Rev Immunol.</source> (<year>2009</year>) <volume>9</volume>:<fpage>741</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nri2629</pub-id><?supplied-pmid 19763148?><pub-id pub-id-type="pmid">19763148</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>Novere N</given-names></name><name><surname>Hucka</surname><given-names>M</given-names></name><name><surname>Mi</surname><given-names>H</given-names></name><name><surname>Moodie</surname><given-names>S</given-names></name><name><surname>Schreiber</surname><given-names>F</given-names></name><name><surname>Sorokin</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The systems biology graphical notation</article-title>. <source>Nat Biotechnol.</source> (<year>2009</year>) <volume>27</volume>:<fpage>735</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.1558</pub-id><pub-id pub-id-type="pmid">19668183</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>E</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Ontobee: A linked ontology data server to support ontology term dereferencing, linkage, query and integration</article-title>. <source>Nucleic Acids Res.</source> (<year>2017</year>) <volume>45</volume>:<fpage>D347</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkw918</pub-id><?supplied-pmid 27733503?><pub-id pub-id-type="pmid">27733503</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heaton</surname><given-names>NS</given-names></name><name><surname>Moshkina</surname><given-names>N</given-names></name><name><surname>Fenouil</surname><given-names>R</given-names></name><name><surname>Gardner</surname><given-names>TJ</given-names></name><name><surname>Aguirre</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>PS</given-names></name><etal/></person-group>. <article-title>Targeting viral proteostasis limits influenza virus, HIV, and dengue virus infection</article-title>. <source>Immunity.</source> (<year>2016</year>) <volume>44</volume>:<fpage>46</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2015.12.017</pub-id><?supplied-pmid 26789921?><pub-id pub-id-type="pmid">26789921</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group>. <article-title>The Ontology of Biological and Clinical Statistics (OBCS)-based statistical method standardization and meta-analysis of host responses to yellow fever vaccines</article-title>. <source>Quantitative Biology.</source> (<year>2017</year>) <volume>5</volume>:<fpage>291</fpage>–<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1007/s40484-017-0122-5</pub-id><?supplied-pmid 30034908?><pub-id pub-id-type="pmid">30034908</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Harris</surname><given-names>MR</given-names></name><name><surname>Masci</surname><given-names>AM</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Hero</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>The Ontology of Biological and Clinical Statistics (OBCS) for standardized and reproducible statistical analysis</article-title>. <source>J Biomed Semantics.</source> (<year>2016</year>) <volume>7</volume>:<fpage>53</fpage>. <pub-id pub-id-type="doi">10.1186/s13326-016-0100-2</pub-id><?supplied-pmid 27627881?><pub-id pub-id-type="pmid">27627881</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozgur</surname><given-names>A</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Radev</surname><given-names>DR</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group>. <article-title>Mining of vaccine-associated IFN-gamma gene interaction networks using the Vaccine Ontology</article-title>. <source>J Biomed Sem.</source> (<year>2011</year>) <volume>2</volume>:<fpage>S8</fpage>. <pub-id pub-id-type="doi">10.1186/2041-1480-2-S2-S8</pub-id><?supplied-pmid 21624163?><pub-id pub-id-type="pmid">21624163</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group>. <article-title>Ontology representation and analysis of vaccine formulation and administration and their effects on vaccine immune responses</article-title>. <source>J Biomed Sem.</source> (<year>2012</year>) <volume>3</volume>:<fpage>17</fpage>. <pub-id pub-id-type="doi">10.1186/2041-1480-3-17</pub-id><?supplied-pmid 23256535?><pub-id pub-id-type="pmid">23256535</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Querec</surname><given-names>TD</given-names></name><name><surname>Akondy</surname><given-names>RS</given-names></name><name><surname>Lee</surname><given-names>EK</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Nakaya</surname><given-names>HI</given-names></name><name><surname>Teuwen</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans</article-title>. <source>Nat Immunol.</source> (<year>2009</year>) <volume>10</volume>:<fpage>116</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1688</pub-id><?supplied-pmid 19029902?><pub-id pub-id-type="pmid">19029902</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Berke</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group>. <article-title>VIO: ontology classification and study of vaccine responses given various experimental and analytical conditions</article-title>. <source>BMC Bioinform.</source> (<year>2019</year>) <volume>20</volume>:<fpage>704</fpage>. <pub-id pub-id-type="doi">10.1186/s12859-019-3194-6</pub-id><?supplied-pmid 31865910?><pub-id pub-id-type="pmid">31865910</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shankar</surname><given-names>RD</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Jujjavarapu</surname><given-names>C</given-names></name><name><surname>Andorf</surname><given-names>S</given-names></name><name><surname>Wiser</surname><given-names>JA</given-names></name><name><surname>Butte</surname><given-names>AJ</given-names></name></person-group>. <article-title>RImmPort: an R/Bioconductor package that enables ready-for-analysis immunology research data</article-title>. <source>Bioinform</source>. (<year>2017</year>) <volume>33</volume>:<fpage>1101</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btw719</pub-id><?supplied-pmid 28057685?><pub-id pub-id-type="pmid">28057685</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Andorf</surname><given-names>S</given-names></name><name><surname>Gomes</surname><given-names>L</given-names></name><name><surname>Dunn</surname><given-names>P</given-names></name><name><surname>Schaefer</surname><given-names>H</given-names></name><name><surname>Pontius</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>ImmPort: disseminating data to the public for the future of immunology</article-title>. <source>Immunol Res.</source> (<year>2014</year>) <volume>58</volume>:<fpage>234</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s12026-014-8516-1</pub-id><?supplied-pmid 24791905?><pub-id pub-id-type="pmid">24791905</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <label>58.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meehan</surname><given-names>TF</given-names></name><name><surname>Masci</surname><given-names>AM</given-names></name><name><surname>Abdulla</surname><given-names>A</given-names></name><name><surname>Cowell</surname><given-names>LG</given-names></name><name><surname>Blake</surname><given-names>JA</given-names></name><name><surname>Mungall</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Logical development of the cell ontology</article-title>. <source>BMC Bioinform.</source> (<year>2011</year>) <volume>12</volume>:<fpage>6</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2105-12-6</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
